Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Change in Accured Expenses (2016 - 2025)

Perspective Therapeutics' Change in Accured Expenses history spans 16 years, with the latest figure at $5.8 million for Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 246.79% year-over-year to $5.8 million; the TTM value through Sep 2025 reached $2.7 million, up 217.65%, while the annual FY2024 figure was $1.9 million, 20.15% up from the prior year.
  • Change in Accured Expenses for Q3 2025 was $5.8 million at Perspective Therapeutics, up from -$2.8 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $5.8 million in Q3 2025 and bottomed at -$2.8 million in Q2 2025.
  • The 5-year median for Change in Accured Expenses is $40000.0 (2021), against an average of $369764.7.
  • The largest YoY upside for Change in Accured Expenses was 3725.0% in 2022 against a maximum downside of 3700.0% in 2022.
  • A 5-year view of Change in Accured Expenses shows it stood at -$19000.0 in 2021, then skyrocketed by 8152.63% to $1.5 million in 2022, then crashed by 69.08% to $473000.0 in 2023, then skyrocketed by 217.55% to $1.5 million in 2024, then soared by 284.89% to $5.8 million in 2025.
  • Per Business Quant, the three most recent readings for CATX's Change in Accured Expenses are $5.8 million (Q3 2025), -$2.8 million (Q2 2025), and -$1.7 million (Q1 2025).